soliqua glp 1 100/33 Patient Assistance Program (PAP) for Diabetes Patients Sanofi releases new meta-analysis data

Heres what to know about why it happens and when it may improve

Therapeutic effects of endogenous incretin hormones and exogenous incretin-based medications in sepsis

It is ideal when you want to inject the smallest possible volume per dose

Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research

GLP-1 medications like semaglutide and tirzepatide are game-changers in the world of medical weight lossbut how long should you actually stay on them

Will improvement in cardiovascular outcomes even be sufficient to reassure patients and payers on the value proposition of these drugs